SG11201606428UA - Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer - Google Patents
Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancerInfo
- Publication number
- SG11201606428UA SG11201606428UA SG11201606428UA SG11201606428UA SG11201606428UA SG 11201606428U A SG11201606428U A SG 11201606428UA SG 11201606428U A SG11201606428U A SG 11201606428UA SG 11201606428U A SG11201606428U A SG 11201606428UA SG 11201606428U A SG11201606428U A SG 11201606428UA
- Authority
- SG
- Singapore
- Prior art keywords
- antagonist
- combination
- treating cancer
- ido1 inhibitor
- ido1
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3023—Lung
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461935714P | 2014-02-04 | 2014-02-04 | |
PCT/US2015/014247 WO2015119944A1 (en) | 2014-02-04 | 2015-02-03 | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201606428UA true SG11201606428UA (en) | 2016-09-29 |
Family
ID=53778374
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201806297VA SG10201806297VA (en) | 2014-02-04 | 2015-02-03 | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
SG11201606428UA SG11201606428UA (en) | 2014-02-04 | 2015-02-03 | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201806297VA SG10201806297VA (en) | 2014-02-04 | 2015-02-03 | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer |
Country Status (17)
Country | Link |
---|---|
US (2) | US20170037125A1 (en) |
EP (1) | EP3102237B1 (en) |
JP (2) | JP2017508785A (en) |
KR (2) | KR20220153677A (en) |
CN (1) | CN106456753B (en) |
AU (1) | AU2015214404B2 (en) |
BR (1) | BR112016017700A2 (en) |
CA (1) | CA2938566A1 (en) |
ES (1) | ES2856330T3 (en) |
HK (1) | HK1232153A1 (en) |
IL (1) | IL247102B2 (en) |
MX (1) | MX2016010080A (en) |
NZ (1) | NZ722891A (en) |
PH (1) | PH12016501550B1 (en) |
RU (1) | RU2744880C1 (en) |
SG (2) | SG10201806297VA (en) |
WO (1) | WO2015119944A1 (en) |
Families Citing this family (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA026785B1 (en) | 2005-05-10 | 2017-05-31 | Инсайт Холдингс Корпорейшн | Modulators of indoleamine 2,3-dioxygenase and methods of using the same |
SI2170959T1 (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
DK2824100T3 (en) | 2008-07-08 | 2018-04-16 | Incyte Holdings Corp | 1,2,5-oxadiazoles as inhibitors of indolamine-2,3-dioxygenase |
ES2705950T3 (en) | 2011-06-03 | 2019-03-27 | Eisai R&D Man Co Ltd | Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds |
EP2911669B1 (en) * | 2012-10-26 | 2024-04-10 | The University of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
EP3049442A4 (en) | 2013-09-26 | 2017-06-28 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
RS59480B1 (en) | 2013-12-12 | 2019-12-31 | Shanghai hengrui pharmaceutical co ltd | Pd-1 antibody, antigen-binding fragment thereof, and medical application thereof |
JOP20200094A1 (en) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | Antibody molecules to pd-1 and uses thereof |
JOP20200096A1 (en) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | Antibody molecules to tim-3 and uses thereof |
MX2017001980A (en) | 2014-08-28 | 2017-05-04 | Eisai R&D Man Co Ltd | High-purity quinoline derivative and method for manufacturing same. |
US9993551B2 (en) | 2014-09-13 | 2018-06-12 | Novartis Ag | Combination therapies of EGFR inhibitors |
UY36351A (en) | 2014-10-14 | 2016-06-01 | Novartis Ag | ANTIBODY MOLECULES THAT JOIN PD-L1 AND USES OF THE SAME |
BR112017017428A2 (en) | 2015-02-25 | 2018-04-03 | Eisai R&D Management Co., Ltd. | " method for suppressing the bitterness of quinoline derivative " |
KR20170122809A (en) * | 2015-03-04 | 2017-11-06 | 머크 샤프 앤드 돔 코포레이션 | A combination of a PD-1 antagonist and a VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer |
KR20180018695A (en) | 2015-06-16 | 2018-02-21 | 가부시키가이샤 프리즘 파마 | Anticancer drug |
CA2991976A1 (en) | 2015-07-13 | 2017-01-19 | Cytomx Therapeutics, Inc. | Anti-pd-1 antibodies, activatable anti-pd-1 antibodies, and methods of use thereof |
CN108472245A (en) * | 2015-11-04 | 2018-08-31 | 因赛特公司 | For indole amine 2,3-dioxygenase inhibition and its pharmaceutical composition and method of indication |
EP4015537A1 (en) * | 2015-12-01 | 2022-06-22 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatments and uses and methods thereof |
CN106883193B (en) * | 2015-12-15 | 2021-10-15 | 上海翰森生物医药科技有限公司 | Indoleamine 2,3-dioxygenase inhibitor as well as preparation method and application thereof |
CN105646389B (en) * | 2016-01-28 | 2019-06-28 | 中国科学院上海有机化学研究所 | A kind of sulfamic acid rouge and its preparation method and application as indoles amine -2,3- dioxygenase inhibitor |
JP2019510744A (en) * | 2016-02-25 | 2019-04-18 | 深▲セン▼市塔吉瑞生物医▲薬▼有限公司Shenzhen TargetRx,Inc. | Substituted oxadiazole compounds, compositions containing the compounds and applications thereof |
WO2017152054A1 (en) * | 2016-03-04 | 2017-09-08 | Cedars-Sinai Medical Center | Polymalic acid based nanoimmunoconjugates and uses thereof |
EP3423087B1 (en) * | 2016-03-04 | 2023-11-15 | IO Biotech APS | Combination therapy against cancer |
WO2017181849A1 (en) * | 2016-04-20 | 2017-10-26 | 江苏豪森药业集团有限公司 | Indoleamine 2,3-dioxygenase inhibitor, preparation method therefor, and application |
CN107304191B (en) * | 2016-04-20 | 2023-09-29 | 上海翰森生物医药科技有限公司 | Indolylamine 2,3-dioxygenase inhibitor and preparation method and application thereof |
WO2018054365A1 (en) | 2016-09-24 | 2018-03-29 | Beigene, Ltd. | NOVEL 5 or 8-SUBSTITUTED IMIDAZO [1, 5-a] PYRIDINES AS SELECTIVE INHIBITORS OF INDOLEAMINE AND/OR TRYPTOPHANE 2, 3-DIOXYGENASES |
WO2018068201A1 (en) * | 2016-10-11 | 2018-04-19 | Nanjing Legend Biotech Co., Ltd. | Single-domain antibodies and variants thereof against ctla-4 |
KR20190084053A (en) | 2016-10-13 | 2019-07-15 | 주노 쎄러퓨티크스 인코퍼레이티드 | Methods and compositions for immune therapy involving tryptophan pathway regulators |
KR102305215B1 (en) | 2016-10-14 | 2021-09-28 | 프리시젼 바이오사이언시스 인코포레이티드 | Engineered meganucleases specific for recognition sequences in the hepatitis B virus genome |
TW201815417A (en) * | 2016-10-21 | 2018-05-01 | 蘇州盛迪亞生物醫藥有限公司 | Combination use of anti-PD-1 antibody and IDO inhibitor in the preparation of a medicament for the treatment of tumor |
AU2017382405B2 (en) | 2016-12-22 | 2021-12-16 | Calithera Biosciences, Inc. | Compositions and methods for inhibiting arginase activity |
CN108218807A (en) * | 2016-12-22 | 2018-06-29 | 上海长森药业有限公司 | A kind of sulfone amidine as indoles amine -2,3- dioxygenase inhibitors and its preparation method and application |
CA3047002A1 (en) | 2017-01-17 | 2018-07-26 | Board Of Regents, The University Of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
CN114920710A (en) * | 2017-04-27 | 2022-08-19 | 鲁南制药集团股份有限公司 | Urea derivatives |
WO2018218137A1 (en) | 2017-05-25 | 2018-11-29 | Leidos, Inc. | Pd-1 and ctla-4 dual inhibitor peptides |
CN109081818B (en) * | 2017-06-14 | 2022-04-22 | 南京华威医药科技集团有限公司 | Novel indoleamine 2, 3-bis-oxidase inhibitors |
WO2018236796A1 (en) * | 2017-06-20 | 2018-12-27 | Tarveda Therapeutics, Inc. | Combination therapies comprising targeted therapeutics |
EP3421607A1 (en) * | 2017-06-29 | 2019-01-02 | Fundación Centro Nacional de Investigaciones Oncológicas Carlos III | Identification and elimination of damaged and/or senescent cells |
CN109206380A (en) * | 2017-07-03 | 2019-01-15 | 上海时莱生物技术有限公司 | Indoleamine 2,3-dioxygenase inhibitor compound and its preparation method and application |
EP3681535A1 (en) * | 2017-09-13 | 2020-07-22 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
CN109897011B (en) * | 2017-12-08 | 2023-10-31 | 上海华汇拓医药科技有限公司 | IDO inhibitor and application thereof |
KR102492187B1 (en) | 2017-12-20 | 2023-01-27 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 3'3' cyclic dinucleotides with phosphonate linkages that activate STING adapter proteins |
EP3728282B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
KR20200120641A (en) | 2018-01-15 | 2020-10-21 | 난징 레전드 바이오테크 씨오., 엘티디. | Single-domain antibody against PD-1 and variants thereof |
KR102526964B1 (en) | 2018-02-26 | 2023-04-28 | 길리애드 사이언시즈, 인코포레이티드 | Substituted pyrrolizine compounds as HBV replication inhibitors |
CA3091414A1 (en) | 2018-02-27 | 2019-09-06 | Leidos, Inc. | Pd-1 peptide inhibitors |
CN110221068B (en) * | 2018-03-02 | 2020-09-18 | 中国医学科学院基础医学研究所 | Application of reagent for detecting Kyn content |
EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
TW202005654A (en) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2'2'-cyclic dinucleotides |
EP3774832A1 (en) | 2018-04-06 | 2021-02-17 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotides |
TWI818007B (en) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-cyclic dinucleotides |
TW201945388A (en) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis B virus genome |
TW202014193A (en) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 2’3’-cyclic dinucleotides comprising carbocyclic nucleotide |
EP3823604A4 (en) | 2018-07-17 | 2022-03-16 | Board of Regents, The University of Texas System | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
KR20210084579A (en) | 2018-10-31 | 2021-07-07 | 길리애드 사이언시즈, 인코포레이티드 | Substituted 6-azabenzimidazole compounds having HPK1 inhibitory activity |
BR112021008255A2 (en) | 2018-10-31 | 2021-08-03 | Gilead Sciences, Inc. | substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
CN111617078B (en) * | 2019-02-28 | 2023-02-03 | 四川科伦博泰生物医药股份有限公司 | Pharmaceutical compositions, methods and uses thereof for the treatment and/or prevention of disease |
CA3129011C (en) | 2019-03-07 | 2023-12-19 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
WO2020178768A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
KR20210137517A (en) | 2019-03-07 | 2021-11-17 | 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. | 2'3'-cyclic dinucleotides and prodrugs thereof |
TW202210480A (en) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
TW202212339A (en) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | Solid forms of a toll-like receptor modulator |
CA3141162A1 (en) | 2019-05-22 | 2020-11-26 | Leidos, Inc. | Lag3 binding peptides |
TWI826690B (en) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | Substituted eneoxindoles and uses thereof |
EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
CA3152263A1 (en) * | 2019-09-25 | 2021-04-01 | Julia SANTUCCI PEREIRA DEL BUONO | Composite biomarker for cancer therapy |
EP4037708A1 (en) | 2019-09-30 | 2022-08-10 | Gilead Sciences, Inc. | Hbv vaccines and methods treating hbv |
US20230031465A1 (en) | 2019-12-06 | 2023-02-02 | Precision Biosciences, Inc. | Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome |
CN115605493A (en) | 2020-03-20 | 2023-01-13 | 吉利德科学公司(Us) | Prodrugs of4'-C-substituted-2-halo-2' -deoxyadenosine nucleosides and methods of making and using the same |
EP4161952A1 (en) | 2020-06-04 | 2023-04-12 | Leidos, Inc. | Immunomodulatory compounds |
US11839659B2 (en) | 2020-07-02 | 2023-12-12 | Northwestern University | Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) protein |
EP4188947A2 (en) | 2020-07-31 | 2023-06-07 | Leidos, Inc. | Lag3 binding peptides |
WO2022081426A1 (en) | 2020-10-12 | 2022-04-21 | Leidos, Inc. | Immunomodulatory peptides |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
EP4052705A1 (en) * | 2021-03-05 | 2022-09-07 | Universität Basel Vizerektorat Forschung | Compositions for the treatment of ebv associated diseases or conditions |
AU2022228701A1 (en) * | 2021-03-05 | 2023-09-14 | Universität Basel | Compositions for the treatment of ebv associated diseases or conditions |
CA3217107A1 (en) | 2021-05-13 | 2022-11-17 | Daniel J. CLOUTIER | Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics |
US11931424B2 (en) | 2021-06-11 | 2024-03-19 | Gilead Sciences, Inc. | Combination MCL-1 inhibitors with anti-body drug conjugates |
CN117651554A (en) | 2021-06-11 | 2024-03-05 | 吉利德科学公司 | Combination of MCL-1 inhibitors and anticancer agents |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CA3220923A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117355531A (en) | 2021-06-23 | 2024-01-05 | 吉利德科学公司 | Diacylglycerol kinase modulating compounds |
CN117396478A (en) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | Diacylglycerol kinase modulating compounds |
CN116444454B (en) * | 2023-06-16 | 2023-09-12 | 中国医学科学院医药生物技术研究所 | N-hydroxy amidine derivative, preparation method and application thereof, and tumor immunotherapy medicament |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
EP1135415B1 (en) | 1998-12-01 | 2010-08-11 | Facet Biotech Corporation | Humanized antibodies to gamma-interferon |
EP2243493A1 (en) | 2002-07-03 | 2010-10-27 | Ono Pharmaceutical Co., Ltd. | Immunopotentiative composition |
ATE514713T1 (en) | 2002-12-23 | 2011-07-15 | Wyeth Llc | ANTIBODIES TO PD-1 AND THEIR USE |
WO2004072286A1 (en) | 2003-01-23 | 2004-08-26 | Ono Pharmaceutical Co., Ltd. | Substance specific to human pd-1 |
MX2007013978A (en) | 2005-05-09 | 2008-02-22 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics. |
CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
US20100055111A1 (en) * | 2007-02-14 | 2010-03-04 | Med. College Of Georgia Research Institute, Inc. | Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells |
SI2170959T1 (en) | 2007-06-18 | 2014-04-30 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | Pd-1 binding proteins |
DK2824100T3 (en) * | 2008-07-08 | 2018-04-16 | Incyte Holdings Corp | 1,2,5-oxadiazoles as inhibitors of indolamine-2,3-dioxygenase |
EP2328919A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Pd-i antagonists and methods for treating infectious disease |
SI2342226T1 (en) | 2008-09-26 | 2016-11-30 | Dana-Farber Cancer Institute Inc. | Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses thereof |
KR101050829B1 (en) * | 2008-10-02 | 2011-07-20 | 서울대학교산학협력단 | Anticancer agents comprising an anti-PD-1 antibody or an anti-PD-L1 antibody |
LT4209510T (en) | 2008-12-09 | 2024-03-12 | F. Hoffmann-La Roche Ag | Anti-pd-l1 antibodies and their use to enhance t-cell function |
JP2013512251A (en) | 2009-11-24 | 2013-04-11 | アンプリミューン、インコーポレーテッド | Simultaneous inhibition of PD-L1 / PD-L2 |
ES2676205T3 (en) * | 2011-03-31 | 2018-07-17 | Merck Sharp & Dohme Corp. | Stable antibody formulations for the human PD-1 receptor of programmed death and related treatments |
TR201820873T4 (en) | 2011-08-01 | 2019-01-21 | Hoffmann La Roche | Methods for treating cancer using Pd-1 axis binding antagonists and mech inhibitors. |
EP2911669B1 (en) * | 2012-10-26 | 2024-04-10 | The University of Chicago | Synergistic combination of immunologic inhibitors for the treatment of cancer |
BR122020009912B1 (en) * | 2013-11-08 | 2022-11-01 | Incyte Holdings Corporation | PROCESS FOR THE SYNTHESIS OF AN INDOLEAMINE 2,3-DIOXYGENASE INHIBITOR |
-
2015
- 2015-02-03 KR KR1020227038461A patent/KR20220153677A/en not_active Application Discontinuation
- 2015-02-03 CA CA2938566A patent/CA2938566A1/en active Pending
- 2015-02-03 WO PCT/US2015/014247 patent/WO2015119944A1/en active Application Filing
- 2015-02-03 AU AU2015214404A patent/AU2015214404B2/en active Active
- 2015-02-03 SG SG10201806297VA patent/SG10201806297VA/en unknown
- 2015-02-03 MX MX2016010080A patent/MX2016010080A/en unknown
- 2015-02-03 CN CN201580018270.8A patent/CN106456753B/en active Active
- 2015-02-03 SG SG11201606428UA patent/SG11201606428UA/en unknown
- 2015-02-03 RU RU2016135519A patent/RU2744880C1/en active
- 2015-02-03 NZ NZ722891A patent/NZ722891A/en unknown
- 2015-02-03 KR KR1020167024024A patent/KR20160108568A/en not_active IP Right Cessation
- 2015-02-03 US US15/116,070 patent/US20170037125A1/en not_active Abandoned
- 2015-02-03 BR BR112016017700A patent/BR112016017700A2/en not_active Application Discontinuation
- 2015-02-03 ES ES15746743T patent/ES2856330T3/en active Active
- 2015-02-03 JP JP2016567473A patent/JP2017508785A/en not_active Withdrawn
- 2015-02-03 EP EP15746743.2A patent/EP3102237B1/en active Active
-
2016
- 2016-08-03 IL IL247102A patent/IL247102B2/en unknown
- 2016-08-04 PH PH12016501550A patent/PH12016501550B1/en unknown
-
2017
- 2017-06-14 HK HK17105931.2A patent/HK1232153A1/en unknown
-
2019
- 2019-04-04 US US16/375,405 patent/US20190270812A1/en active Pending
- 2019-07-29 JP JP2019138570A patent/JP6812512B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US20170037125A1 (en) | 2017-02-09 |
JP2019214589A (en) | 2019-12-19 |
EP3102237A1 (en) | 2016-12-14 |
US20190270812A1 (en) | 2019-09-05 |
KR20160108568A (en) | 2016-09-19 |
ES2856330T3 (en) | 2021-09-27 |
PH12016501550A1 (en) | 2016-10-03 |
CA2938566A1 (en) | 2015-08-13 |
HK1232153A1 (en) | 2018-01-05 |
EP3102237B1 (en) | 2020-12-02 |
RU2744880C1 (en) | 2021-03-16 |
JP2017508785A (en) | 2017-03-30 |
CN106456753A (en) | 2017-02-22 |
IL247102B1 (en) | 2023-03-01 |
EP3102237A4 (en) | 2017-08-02 |
PH12016501550B1 (en) | 2016-10-03 |
BR112016017700A2 (en) | 2017-10-10 |
KR20220153677A (en) | 2022-11-18 |
AU2015214404B2 (en) | 2020-10-01 |
SG10201806297VA (en) | 2018-08-30 |
WO2015119944A1 (en) | 2015-08-13 |
IL247102B2 (en) | 2023-07-01 |
JP6812512B2 (en) | 2021-01-13 |
IL247102A0 (en) | 2016-09-29 |
AU2015214404A1 (en) | 2016-08-18 |
MX2016010080A (en) | 2016-10-07 |
NZ722891A (en) | 2021-07-30 |
CN106456753B (en) | 2021-05-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1232153A1 (en) | Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer pd-1 ido1 | |
IL246760A0 (en) | Combination of a pd-1 antagonist and a vegfr inhibitor for treating cancer | |
HK1252652A1 (en) | Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer | |
IL250187B (en) | Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer | |
IL276314A (en) | Compositions for treating cancer using pd-1 axis binding antagonists and mek inhibitors | |
IL263178A (en) | Pd-1 / pd-l1 inhibitors for cancer treatment | |
IL254131B (en) | Pd-1 / pd-l1 inhibitors for the treatment of cancer | |
IL249658A0 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
IL251584B (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
IL246902B (en) | Dihydropyrrolopyridine inhibitors of ror-gamma | |
IL254133A0 (en) | Combination of a pd-1 antagonist and eribulin for treating cancer | |
WO2016154412A9 (en) | Combination of a pd-1 antagonist and a listeria based vaccine for treating pancreatic cancer | |
EP3481393A4 (en) | COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER |